Search

everythinglearnresearchcommunity

for

Search:↓

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

A user shared their 3.5-year hair loss treatment journey using finasteride and minoxidil, showing significant hair density improvement and no noticeable side effects. The user also mentioned the confidence boost from shaving their head and the positive impact of the treatments.

The post expresses frustration over the unavailability of pure topical finasteride in India despite the developed pharma industry. The user seeks advice on making it at home and its effectiveness.

A user asked if microneedling, massages, and essential oils can prevent further hair loss in the crown area without using drugs. The response indicated that without a 5-alpha-reductase inhibitor, hair loss will likely continue.

A user switched from finasteride to dutasteride and experienced initial shedding but later saw significant hair regrowth, especially with the addition of minoxidil. Another user switched to dutasteride without experiencing shedding or noticeable regrowth.

The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

A user has been using finasteride for 1.5 years and reports significant improvement in hair quality and thickness, but not much change in hairline. They started with a big shed and take 0.5 mg daily.

A user reported positive results after 80 days of using finasteride 1mg daily, along with vitamin D3 supplements. They noticed thicker hair and new baby hairs, and are considering adding minoxidil in the future.

Some people find topical minoxidil effective for hair loss, but oral minoxidil doesn't work for them, possibly due to absorption issues. Others have had better results with oral minoxidil, suggesting individual responses vary.

A user shared their personal experience with hair loss treatment, detailing their journey from initial hairline thinning to regrowth. They tried several protocols, with the most effective being a combination of finasteride, minoxidil, dermarolling, and topical tretinoin, and plan to continue finasteride daily.

A user is testing clascoterone (Winlevi) on their scalp for hair loss and has noticed a reduction in scalp sebum after one month. They are also using other unspecified treatments and plan to provide an update after the second month.

The conversation is about obtaining and the effectiveness of Olumiant for treating hair loss, specifically for someone with early-stage alopecia areata concerned about hair loss around the face. The user is seeking clarity on how to get a prescription for Olumiant.

Hair loss treatments Finasteride and Dutasteride may cause shedding, but it's a good sign as miniaturized hairs are replaced by thicker ones. Shortness of breath may be experienced from Dutasteride or oral Minoxidil.

User asks if dutasteride destroys hairlines. Some users share negative experiences, while others report improvement or no issues. Advice given: start with finasteride and consider anti-androgens if needed.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. User seeks updates on topical treatment Pyrilutamide.

Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.

Users discuss waiting for new hair loss treatments and share struggles with side effects from current options like Minoxidil and Finasteride. They express hope for Pyrilutamide and CosmeRNA to provide better solutions.

Switching from finasteride to dutasteride for treating hair loss, with reports of improved regrowth and little to no side effects.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

The conversation is about the anticipated release timeline for a hair loss treatment called GT20029. It may be available on the gray market in 1-2 years and officially in 3-4 years after completing clinical trials.

A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.

A dermatologist prescribed Betnovate scalp, a corticosteroid, for a 21-year-old male's hair loss due to DHT. The individual is considering using Nizoral shampoo, topical finasteride, a derma roller, and minoxidil, but is unsure about the effectiveness of two other products suggested by the dermatologist.

The user has been using topical finasteride for seven months and minoxidil for three years, with added tretinoin gel for ten months, and is experiencing continuous shedding without signs of regrowth. They are questioning if the amount of shedding is normal at this stage of treatment and if there's a correlation between finasteride response and the rate of hair loss.

The effectiveness of Finasteride/Dutasteride for treating hair loss, and a cautionary tale about potential side effects such as gynecomastia.

Pyrilutamide, a potential hair loss treatment, and how it compares to existing treatments such as Minoxidil, Finasteride and RU58841. Real-world results are being discussed to determine its effectiveness.

Yokohama University and Dr. Fukuda plan human hair multiplication trials in 2023. Users express hope for future hair cloning treatments over current hair transplants.

A monoclonal antibody clinical trial for potential hair loss treatments in Victoria, Australia and the discussion of their efficacy. People shared information about similar drugs already on the market, speculated about potential side effects, and discussed how to spread the word about the trial.

Nearly 40% of adults with alopecia areata achieved at least 80% scalp hair coverage after 52 weeks of taking OLUMIANT® 4-mg. The conversation distinguishes this success from androgenetic alopecia, which is a different type of hair loss.

A user experienced mild side effects from 0.5mg finasteride daily, including increased estradiol and minor gynecomastia. They are considering taking a low dose of exemestane to reduce estrogen levels.